USNA
Usana Health Sciences Inc

518
Mkt Cap
$334.26M
Volume
103,666.00
52W High
$38.32
52W Low
$16.60
PE Ratio
32.35
USNA Fundamentals
Price
$18.11
Prev Close
$18.34
Open
$18.37
50D MA
$19.14
Beta
0.90
Avg. Volume
154,141.57
EPS (Annual)
$0.5793
P/B
0.62
Rev/Employee
$589,335.67
$287.82
Loading...
Loading...
News
all
press releases
USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day
USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day PR Newswire SALT LAKE CITY, April 1, 2026 SALT LAKE...
PR Newswire·10d ago
News Placeholder
More News
News Placeholder
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·11d ago
News Placeholder
Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency
Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for...
PR Newswire·18d ago
News Placeholder
USANA Health Sciences (NYSE:USNA) Director Gilbert Fuller Sells 1,058 Shares
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,058 shares of the business's stock in a transaction on Friday, March 20th. The stock was sold at an average price of $17.00, for a total transaction of $17,986.00. The sale was disclosed in a legal filing with...
MarketBeat·21d ago
News Placeholder
Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells 1,058 Shares of Stock
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,058 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $17.00, for a total transaction of $17,986.00. The transaction was disclosed in a filing...
MarketBeat·22d ago
News Placeholder
EHC Stock: Do Valuation and Expansion Trends Support a Hold Strategy?
EHC is expanding its inpatient rehab network and posting steady revenue and cash-flow growth, but Medicaid policy risks and higher debt remain concerns.
Zacks·26d ago
News Placeholder
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Zacks·26d ago
News Placeholder
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.
Zacks·29d ago
News Placeholder
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.
Zacks·29d ago
News Placeholder
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
Zacks·1mo ago
<
1
2
...
>

Latest USNA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.